

Classification	ESG Policy	Global Initiative Participation Policy	Rev. Date	09. 2023
Page	1		Rev. No.	1.1

Revision No.	Revision Date
1.1	September 21, 2023
1.0	August 10, 2023
0.1	August 27, 2021

SK Biopharmaceuticals endeavors to comply with the Codes of Conduct and guidelines of global ESG standards by taking part in relevant global ESG initiatives. Following the trend of the creation of various global ESG initiatives, SK Biopharmaceuticals expands its voluntary participation in industry-related initiatives. We expect such efforts will result in the enhancement of our global competitiveness through active information exchange and partnership.

Under the principle of partnership participation, SK Biopharmaceuticals devotes to effective communications with the stakeholders and improving the executive ability to realize its sustainable management. As the first signatory in the Republic of Korea, SK Biopharmaceuticals joined PSCI (Pharmaceutical Supply Chain Initiative) in April 2022 and has taken the role of Associate member of the Audit Committee at PSCI since October 2022. Also, by participating in the UNGC (United Nations Global Compact) membership in May 2023, SK Biopharmaceuticals has applied the UNGC's 10 Principles to the company-wide strategic management and contributed to achieving UN SDGs by enlightening its employees' recognition of the principles.

Roadmap of Global Initiative Participation

Below are the stepwise goals to expand the level of SKBP's participation in global initiatives.



Classification	ESG Policy	Global Initiative Participation Policy	Rev. Date	09. 2023
Page	2		Rev. No.	1.1

Our Principle for Partnership Participation

① Conformity of the SK Biopharmaceuticals' key areas for sustainable management and main goals

- review participations in global initiatives that meets our key areas for sustainable management and strategic direction.
- proceed with the conformity of 1) business areas, 2) scale, 3) business direction with clear purposes.

② Participation in the industry-specific initiatives

- actively drive participation in the pharmaceutical industry-specific initiatives.

③ Consideration of internal and external impacts

- analyze and review impacts on its business and external stakeholders when joining a global initiative.

④ Partnerships that align with the performances of ESG management

- review additional needs of improvements of ESG management and revision of detailed ESG goals and carry forward consistent enhancements by participation in global initiatives.